Christophe Le Tourneau is Senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i), as well as the Head and Neck Clinic. Christophe is leading the early phase clinical trials program of the Institut Curie.
Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program.
His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advanced cancer. Christophe Le Tourneau is leading several precision medicine projects at the national and international level. He is the vice-chair of the GORTEC head and neck cancer group.
Christophe has participated in the Developmental Therapeutics track of the ASCO from 2017 to 2019 and has been the track leader in 2018. He has been a member of the Developmental Therapeutics and the Head and Neck Cancer tracks on several occasions. He has published 200+ peer-reviewed papers in international journals.
Christophe Le Tourneau is Chair, Clinical Trials Committee, WIN Consortium.